ANEB — Anebulo Pharmaceuticals Balance Sheet
0.000.00%
Last trade - 00:00- $94.08m
- $83.73m
- 33
- 12
- 94
- 43
Annual balance sheet for Anebulo Pharmaceuticals, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 20 | 14.5 | 11.2 | 3.09 | 11.6 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0 | — | — | — | 0.073 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 21.7 | 15.6 | 11.7 | 3.51 | 12 |
| Other Long Term Assets | |||||
| Total Assets | 21.7 | 15.6 | 11.7 | 4.07 | 12.1 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Current Liabilities | 0.242 | 0.513 | 1.07 | 0.261 | 0.488 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Liabilities | 0.242 | 0.513 | 1.07 | 0.261 | 0.488 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 21.4 | 15.1 | 10.6 | 3.81 | 11.7 |
| Total Liabilities & Shareholders' Equity | 21.7 | 15.6 | 11.7 | 4.07 | 12.1 |
| Total Common Shares Outstanding |